Covered recipient · General Payments record
SUSAN E JANOCIK
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,720.43
- Reported across 216 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $248.49 | 19 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $132.86 | 13 |
| Novo Nordisk AS | $57.83 | 3 |
| ABBVIE INC. | $21.16 | 1 |
| Acerta Pharma LLC | $19.02 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $17.62 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.16 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103987900 | CMS |
| Amgen Inc. | $10.20 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760939 | CMS |
| Amgen Inc. | $8.46 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760947 | CMS |
| Amgen Inc. | $9.63 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760954 | CMS |
| Amgen Inc. | $9.36 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117588021 | CMS |
| Amgen Inc. | $8.01 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760964 | CMS |
| Amgen Inc. | $9.86 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760970 | CMS |
| Amgen Inc. | $13.60 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760977 | CMS |
| Amgen Inc. | $9.43 | 07/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117588023 | CMS |
| Amgen Inc. | $14.35 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760987 | CMS |
| Amgen Inc. | $10.16 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115760993 | CMS |
| Amgen Inc. | $11.55 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115761001 | CMS |
| Amgen Inc. | $8.96 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117588025 | CMS |
| Amgen Inc. | $9.29 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115761009 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.02 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104197367 | CMS |
| Novartis Pharmaceuticals Corporation | $17.62 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087147952 | CMS |
| Novo Nordisk Inc | $18.18 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097489708 | CMS |
| Novo Nordisk Inc | $19.65 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097787037 | CMS |
| Novo Nordisk Inc | $20.00 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096865819 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.